ReviewFrontiers in immunology2025
Sepsis-driven metabolic reprogramming shapes cancer immunotherapy efficacy, metastatic potential, and drug sensitivity.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis and cancer interact in a complex, bidirectional manner that significantly impacts patient prognosis, with metabolic reprogramming being a key factor. Sepsis-induced immune dysregulation and metabolic changes promote immunosuppression, tumor growth, metastasis, and resistance to immunotherapy. Cancer patients, especially those on immunosuppressive therapies, are more vulnerable to sepsis, complicating treatment and worsening outcomes. An integrated approach combining immunotherapy, metabolic interventions, and antimicrobial strategies is essential, alongside identifying biomarkers for personalized care. Recent advancements emphasize the need to integrate molecular insights, immunotherapy, and drug sensitivity analysis. This review explores how sepsis-driven metabolic reprogramming affects cancer immunotherapy and metastasis, providing a foundation for future integrated treatment strategies. Further research should focus on developing precise therapies that regulate metabolism, immunity, and the microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.